EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes

Yanjing Peng, Panjian Wei, Meng Gu, Guirong Wang, Teng Ma, Jinjing Tan iD

Viruses · 2025

DOI: 10.3390/v17101314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Yanjing Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China. Hauptthemen laut MEDLINE: COVID-19, Lung Neoplasms, Tumor Microenvironment. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic prompted investigation into the interaction between SARS-CoV-2 infection and immune checkpoint inhibitor (ICI) therapy in lung cancer patients. Understanding this interplay is crucial for optimizing cancer immunotherapy.

Methods

A retrospective analysis was conducted on lung cancer patients, characterizing changes in peripheral immune cells and plasma cytokines (including IL-10 and IL-12p70) before, during, and after SARS-CoV-2 infection. Progression-free survival (PFS) was compared between ICI-treated patients with and without COVID-19. Cytokine dynamics were further analyzed in a non-infected cohort.

Results

SARS-CoV-2 infection induced a prolonged systemic cytokine storm, with elevated IL-10 and IL-12p70 levels and reduced monocyte proportions lasting up to 10 weeks post-recovery. Despite this immune perturbation, COVID-19 did not impair long-term PFS; instead, a transient improvement in disease control was observed in infected patients. In non-infected patients, sustained or increased IL-10 and IL-12p70 levels during ICI therapy were associated with longer PFS (p < 0.05).

Conclusions

SARS-CoV-2 infection transiently alters the immune landscape in lung cancer patients without compromising ICI efficacy. The sustained elevation of IL-10 and IL-12p70 may contribute to short-term clinical benefits. Monitoring cytokine dynamics could serve as a prognostic tool for predicting ICI response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Lung NeoplasmsTumor MicroenvironmentHumansFemaleMaleRetrospective StudiesMiddle AgedAgedImmunotherapySARS-CoV-2Treatment OutcomeInterleukin-10Immune Checkpoint InhibitorsCytokinesInterleukin-12Aged, 80 and overCytokine Release Syndrome

Stichwörter der Autor:innen

COVID-19 and lung cancerImmune Checkpoint Inhibitors (ICI)Progression-Free Survival (PFS)cytokine dynamicsimmune landscape alteration

Substanzen

Interleukin-10Immune Checkpoint InhibitorsCytokinesInterleukin-12

Autor:innen und Institutionen

  • Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
  • Department of Laboratory Medicine, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.

ORCID-Profile: Jinjing Tan

Zitieren

APA

Peng, Y., Wei, P., Gu, M., Wang, G., Ma, T., & Tan, J. (2025). SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes. Viruses. https://doi.org/10.3390/v17101314

Vancouver

Peng Y, Wei P, Gu M, Wang G, Ma T, Tan J. SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes. Viruses. 2025. doi:10.3390/v17101314

BibTeX
@article{Peng2025,
  author = {Peng, Yanjing and Wei, Panjian and Gu, Meng and Wang, Guirong and Ma, Teng and Tan, Jinjing},
  title = {SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17101314}
}
Kostenlos starten →